NCT01591837View on ClinicalTrials.gov

A Study to Assess the Immunogenicity and Safety of CSL's 2012/2013 Formulation of Enzira® Vaccine in Healthy Volunteers

PHASE4CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

June 30, 2012

Study Completion Date

June 30, 2012

Conditions
Influenza, Human
Interventions
BIOLOGICAL

CSL Influenza Vaccine

The study vaccine (CSL Influenza Vaccine) is a sterile, thiomersal-free suspension containing 45 mcg total haemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2012/2013 influenza season). The vaccine will be administered by intramuscular or subcutaneous injection.

Trial Locations (1)

NW10 7EW

Study Site, London

All Listed Sponsors
lead

Seqirus

INDUSTRY

NCT01591837 - A Study to Assess the Immunogenicity and Safety of CSL's 2012/2013 Formulation of Enzira® Vaccine in Healthy Volunteers | Biotech Hunter | Biotech Hunter